Stay updated on CT-P16 vs Avastin in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the CT-P16 vs Avastin in Lung Cancer Clinical Trial page.

Latest updates to the CT-P16 vs Avastin in Lung Cancer Clinical Trial page
- Check2 days agoChange DetectedAn NIH-wide notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check9 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 on the page displaying a 403 error.SummaryDifference0.2%

- Check16 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe study page now displays a 403 Forbidden message, replacing the usual study details with an access-restricted notice.SummaryDifference17%

- Check58 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, signaling a new platform release. This change does not modify the study details or the information presented on the page.SummaryDifference0.1%

- Check80 days agoChange Detected- Added a new publication citation: Kim T, Kim H, Lee H, Ahn K, Park T, Baek H, Chang MJ. Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin(R) and US-Avastin(R) in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. BioDrugs. 2026 Aug 2. Online ahead of print. - Page revision updated from v3.6.4 to v3.6.5.SummaryDifference0.1%

Stay in the know with updates to CT-P16 vs Avastin in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CT-P16 vs Avastin in Lung Cancer Clinical Trial page.